TT/I  University of Arkansas for Medical Sciences

     Office Locations:

401 South Cedar Street
Little Rock, AR 72205
Phone: 501-686-6696
Fax: 501-686-8501



  • Early
  • Seed



  • Life Sciences & Healthcare
  • Medical Device



    UAMS Arkansas BioVentures and its Technology Licensing Office (TLO) were established as a formal outgrowth of the University of Arkansas for Medical Sciences' (UAMS) interest in translating its research into products that benefit human health. The UAMS College of Medicine established UAMS BioVentures in 1997 to maximize global, industrial interaction with the University of Arkansas faculty, as well as to facilitate technology transfer, the creation of startup companies that are based on UAMS technology invention disclosure, and contributions to Arkansas' economic development. UAMS' primary missions is to translate publicly funded research into products that benefit human healthcare and convert Arkansas' medical and biotechnology research into new companies and high wage jobs for Arkansans. BioVentures offers the UAMS client companies access to many University resources, both at UAMS and at the University of Arkansas at Little Rock (UALR), and a 16,500 square foot new business incubator facility. This facility also houses GMP (Good Manufacturing Practice) laboratories and production space that has been qualified to support the development of clinical research. UAMS is the stateā€™s largest basic and applied research institution, with a total budget of $1.3 billion and more than $100 million in annual research funding.

    Investment Firm Key

       VC = Venture Capital
       PE = Private Equity
       A = Angel
       I = Incubator
       MB = Merchant Bank
       VD = Venture Debt
       FI = Family Investment Office
       FOF = Fund of Funds
       ED = Economic Development Office   
       TT = Technology Transfer Office
       CVC = Corporate Venture Capital
       SEC = Secondary Purchaser
       HF = Hedge Fund/Mutual Fund
    Venture Capital
    Seed Stage
    (includes "pre-seed," or
    concept stage)
    No Revenue
    Early StageMinimal
    Growth Stage
    (also called Mid-stage)
    Expansion Stage
    (also called Late-stage)
    $7M and greater
    Private Equity
    Lower Middle Market$10M-$249M
    Middle Market$250M-$499M
    Upper Middle Market$500M-$1B
    Large Cap>$1B

    Investment Team:

    Name   Title
    Get the complete investment team + individual email addresses for investment team partners. Get personal images, LinkedIn links, investment specialties, office locations and more with a National Database subscription.
    Kevin Sexton MD Interim Director


    Portfolio companies include:


    Recent News: